 LONDON, Jan. 05, 2022 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences: 